Biotech

Biotech catch-all — only use if no sub-Sector applies. Editors should pick a sub-Sector first; only fall back to this term when nothing more specific fits. Mirrors the catch-all pattern on the Datatech, Fintech and Disrupts brands.
Biotech

Linnaeus Therapeutics' LNS8801 selected for NIA lifespan testing

The GPER agonist joins the NIA's Interventions Testing Programme, complementing a separate $22m ARPA-H contract to evaluate healthspan preservation.
The GPER agonist joins the NIA's Interventions Testing Programme, complementing a separate $22m ARPA-H contract to evaluate healthspan preservation.
The Biotech Times Editorial Team  · 
Regulatory Science
Biotech

Humacyte ATEV beats AV fistula on catheter-free days in Phase 3

Humacyte's bioengineered vessel delivered 91 more catheter-free days than standard-of-care AV fistula in female dialysis patients, triggering a supplemental BLA filing.
Humacyte's bioengineered vessel delivered 91 more catheter-free days than standard-of-care AV fistula in female dialysis patients, triggering a supplemental BLA filing.
The Biotech Times Editorial Team  · 
Biotech

Atavistik Bio wins FDA IND clearance and Fast Track tag for ATV-1601

The Cambridge biotech can now advance directly into a randomised Phase 1/2 study of its oral AKT1 inhibitor in hereditary haemorrhagic telangiectasia.
The Cambridge biotech can now advance directly into a randomised Phase 1/2 study of its oral AKT1 inhibitor in hereditary haemorrhagic telangiectasia.
The Biotech Times Editorial Team  · 
Biotech

Nurix and Roche strike $2.3bn BTK degrader collaboration

Nurix Therapeutics receives $700m upfront from Roche to co-develop bexobrutideg across blood cancers, multiple sclerosis and urticaria.
Nurix Therapeutics receives $700m upfront from Roche to co-develop bexobrutideg across blood cancers, multiple sclerosis and urticaria.
The Biotech Times Editorial Team  · 
Biotech

GNI Group to acquire Ayumi Pharmaceutical in ¥44.8bn deal

The Tokyo-listed biopharmaceutical group is buying Blackstone's Japanese specialty pharma asset to build a cross-Pacific commercial platform.
The Tokyo-listed biopharmaceutical group is buying Blackstone's Japanese specialty pharma asset to build a cross-Pacific commercial platform.
The Biotech Times Editorial Team  · 
Biotech

SynCardia's Emperor TAH completes next-gen preclinical implant series

Picard Medical said three acute animal implant procedures demonstrated stable full circulatory support for its fully implantable artificial heart platform.
Picard Medical said three acute animal implant procedures demonstrated stable full circulatory support for its fully implantable artificial heart platform.
The Biotech Times Editorial Team  · 
Biotech

Zealand Pharma petrelintide hits 10.7% weight loss at 42 weeks

Phase 2 ZUPREME-1 data show the amylin analogue achieved double-digit weight reduction with near-placebo tolerability, ahead of planned Phase 3 initiation.
Phase 2 ZUPREME-1 data show the amylin analogue achieved double-digit weight reduction with near-placebo tolerability, ahead of planned Phase 3 initiation.
The Biotech Times Editorial Team  · 
Biotech

Hengrui and Kailera report ribupatide Phase 2 oral data at ADA 2026

Oral ribupatide delivered up to 12.1% mean weight loss at 26 weeks in a China Phase 2 trial, with no observed plateau and a
Oral ribupatide delivered up to 12.1% mean weight loss at 26 weeks in a China Phase 2 trial, with no observed plateau and a
The Biotech Times Editorial Team  · 
Biotech

Ona Therapeutics raises $86.6m Series B to bring ADCs into clinic

The Barcelona biotech closed an oversubscribed round to advance its lead ADC, ONA-255, toward clinical proof of concept in breast cancer.
The Barcelona biotech closed an oversubscribed round to advance its lead ADC, ONA-255, toward clinical proof of concept in breast cancer.
The Biotech Times Editorial Team  · 
Diagnostics
Biotech

ACTG launches Phase 2 trial of dasatinib to shrink HIV reservoir

The global trials network has opened study A5413, testing whether the repurposed cancer drug dasatinib can reduce latent HIV by blocking CD4 cell proliferation.
The global trials network has opened study A5413, testing whether the repurposed cancer drug dasatinib can reduce latent HIV by blocking CD4 cell proliferation.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy
Biotech

Legend Biotech reports 100% ORR in Phase 1 in vivo CAR-T NHL trial

LB2501, a single-infusion in vivo CAR-T candidate, achieved 100% objective response in six relapsed/refractory NHL patients with no dose-limiting toxicities.
LB2501, a single-infusion in vivo CAR-T candidate, achieved 100% objective response in six relapsed/refractory NHL patients with no dose-limiting toxicities.
The Biotech Times Editorial Team  · 
Biotech

JJP Biologics: nebaprubart shows early efficacy in rare LAD trial

Interim Phase 1b data show rapid blister reduction and dapsone tapering in Linear IgA Disease, supporting a rheumatoid arthritis trial in Q3 2026.
Interim Phase 1b data show rapid blister reduction and dapsone tapering in Linear IgA Disease, supporting a rheumatoid arthritis trial in Q3 2026.
The Biotech Times Editorial Team  · 
Digital Health
Biotech

Transplants.org launches as transplant patient navigation platform

The US nonprofit has launched a centralised education and care navigation platform for organ and stem cell transplant patients, backed by 25 leading transplant centres.
The US nonprofit has launched a centralised education and care navigation platform for organ and stem cell transplant patients, backed by 25 leading transplant centres.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biotech

Novo Nordisk raises 2026 guidance as Wegovy pill tops 2m prescriptions

Novo Nordisk lifted its full-year outlook after Wegovy pill surpassed two million prescriptions since its January launch, despite US pricing pressure denting adjusted
Novo Nordisk lifted its full-year outlook after Wegovy pill surpassed two million prescriptions since its January launch, despite US pricing pressure denting adjusted
The Biotech Times Editorial Team  · 
Genomics
Biotech

Madrigal licenses Arrowhead's PNPLA3 siRNA for $1bn in MASH push

Madrigal Pharmaceuticals has licensed ARO-PNPLA3 from Arrowhead, targeting a common genetic driver of MASH prevalent in Hispanic patients.
Madrigal Pharmaceuticals has licensed ARO-PNPLA3 from Arrowhead, targeting a common genetic driver of MASH prevalent in Hispanic patients.
The Biotech Times Editorial Team  · 
Biotech

Kymera Therapeutics unveils KT-579 IBD preclinical data at DDW

Kymera's oral IRF5 degrader matched or outperformed JAK inhibitors and biologics in a preclinical IBD model; Phase 1 human data are due in the
Kymera's oral IRF5 degrader matched or outperformed JAK inhibitors and biologics in a preclinical IBD model; Phase 1 human data are due in the
The Biotech Times Editorial Team  · 
Biotech

Integra LifeSciences posts Q1 revenue of $391.9m amid leadership change

The medical technology group beat its adjusted EPS guidance and named Stuart Essig as CEO as its Tissue Reconstruction unit led organic growth.
The medical technology group beat its adjusted EPS guidance and named Stuart Essig as CEO as its Tissue Reconstruction unit led organic growth.
The Biotech Times Editorial Team  · 
Biotech

InflaRx prices $150m share offering to fund complement pipeline

The Jena-based biopharmaceutical company sold 75 million ordinary shares at $2.00 each, attracting a broad syndicate of healthcare-focused institutional investors.
The Jena-based biopharmaceutical company sold 75 million ordinary shares at $2.00 each, attracting a broad syndicate of healthcare-focused institutional investors.
The Biotech Times Editorial Team  · 
Biotech

Hemab Therapeutics prices upsized IPO at $18 per share on Nasdaq

The coagulation-disorder biotech raised approximately $301.5m gross, listing under ticker COAG with two clinical-stage antibody programmes in its pipeline.
The coagulation-disorder biotech raised approximately $301.5m gross, listing under ticker COAG with two clinical-stage antibody programmes in its pipeline.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biotech

Electra Therapeutics doses first patient in ipsoprubart T cell trial

Electra's SIRP-targeting monoclonal antibody enters a dedicated Phase 1 study in T cell malignancies, supported by a 100% tumour response rate in a
Electra's SIRP-targeting monoclonal antibody enters a dedicated Phase 1 study in T cell malignancies, supported by a 100% tumour response rate in a
The Biotech Times Editorial Team  · 
Subscribe to Biotech